An update on hereditary angioedema

Current Opinion in Pediatrics

Volumn 24, Issue 5, 2012, Pages 638-646

  Hsu, Derek ^a   Shaker, Marcus ^a,b  

^a DARTMOUTH MEDICAL SCHOOL   (United States)

^b CHILDREN S HOSPITAL AT DARTMOUTH   (United States)

Author keywords

Ecallantide; hereditary angioedema; icatibant; plasma derived C1 esterase inhibitor; prophylaxis; recombinant human C1 esterase inhibitor

Indexed keywords

AMINOCAPROIC ACID; ANDROGEN; ANTIFIBRINOLYTIC AGENT; COMPLEMENT COMPONENT C1S INHIBITOR; DANAZOL; ECALLANTIDE; ICATIBANT; OXANDROLONE; STANOZOLOL; TRANEXAMIC ACID;

ANGIONEUROTIC EDEMA; CLINICAL ASSESSMENT; CLINICAL FEATURE; COMPLEMENT BLOOD LEVEL; COST BENEFIT ANALYSIS; DISEASE EXACERBATION; DRUG APPROVAL; HUMAN; NONHUMAN; PATHOPHYSIOLOGY; PATIENT COUNSELING; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROPHYLAXIS; QUALITY OF LIFE; REVIEW;

ADOLESCENT; ALGORITHMS; ANGIOEDEMAS, HEREDITARY; BRADYKININ; CHILD; CHILD, PRESCHOOL; COMPLEMENT C1 INHIBITOR PROTEIN; EVIDENCE-BASED MEDICINE; FEMALE; HUMANS; INFANT; KALLIKREINS; MALE; PEPTIDES; PRACTICE GUIDELINES AS TOPIC; RECEPTORS, BRADYKININ; TREATMENT OUTCOME; UNITED STATES;

EID: 84866360395     PISSN: 10408703     EISSN: 1531698X     Source Type: Journal    
DOI: 10.1097/MOP.0b013e328357b25e     Document Type: Review

References (52)

1. Bork K, Meng G, Staubach P, Hardt J. Hereditary angioedema: new findings concerning symptoms, affected organs, and course. Am J Med 2006; 119:267-274. doi: 10.1016/j.amjmed.2005.09.064.
2. Sardana N, Craig T J. Recent advances in management and treatment of hereditary angioedema. Pediatrics 2011; 128:1173-1180. doi: 10.1542/peds.2011- 0546.
3. Donaldson VH, Evans RR. A biochemical abnormality in hereditary angio-neurotic edema: absence of serum inhibitor of C' 1-esterase. Am JMed 1963; 35:37-44.
4. Bowen T. Hereditary angioedema: beyond international consensus-circa December 2010-The Canadian Society of Allergy and Clinical Immunology Dr David McCourtie Lecture. Allergy Asthma Clin Immunol 2011; 7:1. doi: 10.1186/1710-1492-7-1.
5. Caballero T, Baeza ML, Cabanas R, et al. Consensus statement on the diagnosis, management, and treatment of angioedema mediated by brady-kinin. Part I. Classification, epidemiology, pathophysiology, genetics, clinical symptoms, and diagnosis [Consensus Development Conference, Multicenter Study, Research Support, Non-US Gov't, Review]. J Investig Allergol Clin Immunol 2011; 21:333-347; quiz follow 347.
6. Rosen FS, Pensky J, Donaldson V, Charache P. Hereditary angioneurotic edema: two genetic variants. Science 1965; 148:957-958.
7. Cugno M, Cicardi M, Bottasso B, et al. Activation of the coagulation cascade in C1-inhibitor deficiencies. Blood 1997; 89:3213-3218.
8. Cugno M, Nussberger J, Cicardi M, Agostoni A. Bradykinin and the patho-physiology of angioedema. Int Immunopharmacol 2003; 3:311-317. doi: 10.1016/S1567-5769(02)00162-5.
9. Demirturk M, Polat N, Guz G, et al. There is an increased risk of athero-sclerosis in hereditary angioedema. Int Immunopharmacol 2012; 12:212-doi: 10.1016/j.intimp.2011.11.013.
10. Czucz J, Schaffer G, Csuka D, et al. Endothelial cell function in patients with hereditary angioedema: elevated soluble e-selectin level during inter-attack periods. J Clin Immunol 2012; 32:61-69. doi: 10.1007/s10875-011- 9606-7.
11. http://www.cinryze.com/pdfs/cinryze-prescribing-information.pdf. [Accessed 22 November 2011]
12. Relan A, Bakhtiari K, van Amersfoort ES, et al. Recombinant C1-inhibitor: effects on coagulation and fibrinolysis in patients with hereditary angioedema [Research Support, Non-US Gov't]. BioDrugs 2012; 26:43-52. doi: 10.2165/11599490-000000000-00000.
13. Gosswein T, Kocot A, Emmert G, et al. Mutational spectrum of the C1INH (SERPING1) gene in patients with hereditary angioedema [Research Support, Non-US Gov't]. Cytogenet Genome Res 2008; 121:181-188. doi: 10.1159/000138883.
14. Bork K, Wulff K, Meinke P, et al. A novel mutation in the coagulation factor 12 gene in subjects with hereditary angioedema and normal C1-inhibitor [Case reports]. Clin Immunol 2011; 141:31-35. doi: 10.1016/j.clim.2011.07.002.
15. Farkas H, Varga L, Szeplaki G, et al. Management of hereditary angioedema in pediatric patients. Pediatrics 2007; 120:e713-722. doi: 10.1542/peds. 2006-3303.
16. Farkas H. Pediatric hereditary angioedema due to C1-inhibitor deficiency. Allergy Asthma Clin Immunol 2010; 6:18. doi: 10.1186/1710-1492-6-18.
17. Zuraw BL. Clinical practice. Hereditary angioedema. N Engl J Med 2008; 359:1027-1036. doi: 10.1056/NEJMcp0803977.
18. Jacobs J. Recurrent attacks of hereditary angioedema: a case of delayed diagnosis. Allergy Asthma Proc 2011; 32 (Suppl1):S23-S26. doi: 10.2500/aap.2011.32.3486.
19. Banerji A. Hereditary angioedema: classification, pathogenesis, and diagnosis [Research Support, Non-US Gov't]. Allergy Asthma Proc 2011; 32:403-407. doi: 10.2500/aap.2011.32.3492.
20. Bernstein JA. Update on angioedema: evaluation, diagnosis, and treatment [Research Support, Non-US Gov't]. Allergy Asthma Proc 2011; 32:408-412. doi: 10.2500/aap.2011.32.3469.
21. Busse PJ. Angioedema: differential diagnosis and treatment. Allergy Asthma Proc 2011; 32 (Suppl 1):S3-S11. doi: 10.2500/aap.2011.32.3464.
22. Verdi M, Shaker M. An update on hereditary angioedema [Case Reports]. Adv Emerg Nurs J 2011; 33:163-178; quiz 179-180. doi: 10.1097/TME.0b013e318217b015.
23. Malik SS, Uppal H, Sinha A, et al. Acute paediatric compartment syndrome of the hand caused byhereditary angiooedema [Case Reports]. Ann R Coll Surg Engl 2011; 93:e138-140. doi: 10.1308/147870811X602159.
24. Bowen T, Cicardi M, Farkas H, et al. 2010 International consensus algorithm for the diagnosis, therapy and management of hereditary angioe-dema. Allergy Asthma Clin Immunol 2010; 6:24. doi: 10.1186/1710-1492-6-24.
25. Frazer-Abel A, Giclas PC. Update on laboratory tests for the diagnosis and differentiation of hereditary angioedema and acquired angioedema. Allergy Asthma Proc 2011; 32 (Suppl 1):S17-S21. doi: 10.2500/aap.2011.32.3472.
26. Csuka D, Kelemen Z, Czaller I, et al. Association of celiac disease and hereditary angioedema due to C1-inhibitor deficiency. Screening patients with hereditary angioedema for celiac disease: is it worth the effort? Eur J Gastroenterol Hepatol 2011; 23:238-244. doi: 10.1097/MEG. 0b013e328343d3b2.
27. Csuka D, Varga L, Farkas H, Fust G. Strong correlation of high EBNA-1-IgG levels with edematous attacks involving upper airway mucosa in hereditary angioedema due to C1-inhibitor deficiency [Research Support, Non-US Gov't]. Mol Immunol 2012; 49:649-654. doi: 10.1016/j.molimm.2011.11.005.
28. Farkas H, Varga L. Ecallantide is a novel treatment for attacks of hereditary angioedema due to C1 inhibitor deficiency. Clin Cosmet Investig Dermatol 2011; 4:61-68. doi: 10.2147/CCID.S10322.
29. Christiansen SC, Zuraw BL. Hereditary angioedema: management of laryn-geal attacks. Am J Rhinol Allergy 2011; 25:379-382. doi: 10.2500/ajra. 2011.25.3670.
30. Craig TJ, Levy RJ, Wasserman RL, et al. Efficacy of human C1 esterase inhibitor concentrate compared with placebo in acute hereditary angioedema attacks [Clinical Trial, Phase II, Clinical Trial, Phase III, Multicenter Study, Randomized Controlled Trial]. J Allergy Clin Immunol 2009; 124:801-808. doi: 10.1016/j.jaci.2009.07.017.
31. Hack CE, Relan A, van Amersfoort ES, Cicardi M. Target levels of functional C1-inhibitor in hereditary angioedema. Allergy 2011; 67:123-130. doi: 10.1111/j.1398-9995.2011.02716.x.
32. Craig TJ, Bewtra AK, Bahna SL, et al. C1 esterase inhibitor concentrate in 1085 hereditary angioedema attacks: final results of the I.M.P.A.C.T. 2 study. Allergy 2011; 66:1604-1611. doi: 10.1111/j.1398-9995.2011.02702.x.
33. Riedl MA, Hurewitz DS, Levy R, et al. Nanofiltered C1 esterase inhibitor (human) for the treatment of acute attacks of hereditary angioedema: an open-label trial [Clinical Trial, Multicenter Study, Research Support, Non-US Gov't]. Ann Allergy Asthma Immunol 2012; 108:49-53. doi: 10.1016/j.anai. 2011.10.017.
34. Tilles SA, Borish L. A new generation of hereditary angioedema treatments: remarkable advances clash with disturbing economic reality. Ann Allergy Asthma Immunol 2011; 106:264-266. doi: 10.1016/j.anai.2011.01.025.
35. Tourangeau LM, Castaldo AJ, Davis DK, et al. Safety and efficacy of physician-supervised self-managed C1 inhibitor replacement therapy. Int Arch Allergy Immunol 2011; 157:417-424. doi: 10.1159/000329635.
36. Banta E, Horn P, Craig TJ. Response to ecallantide treatment of acute attacks of hereditary angioedema based on time to intervention: results from the EDEMA clinical trials [Clinical Trial, Phase III, Randomized Controlled Trial, Research Support, Non-US Gov't]. Allergy Asthma Proc 2011; 32:319-324. doi: 10.2500/aap.2011.32.3440.
37. Sheffer AL, Campion M, Levy RJ, et al. Ecallantide (DX-88) for acute hereditary angioedema attacks: integrated analysis of 2 double-blind, phase 3 studies [Clinical Trial, Phase III, Randomized Controlled Trial, Research Support, Non-US Gov't]. J Allergy Clin Immunol 2011; 128:153-159; e154. doi: 10.1016/j.jaci.2011.03.006.
38. Cronin JA, Maples KM. Treatment of an acute attack of type III hereditary angioedema with ecallantide [Case Reports, Letter]. Ann Allergy Asthma Immunol 2012; 108:61-62. doi: 10.1016/j.anai.2011.09.020.
39. Cicardi M, Banerji A, Bracho F, et al. Icatibant, a new bradykinin-receptor antagonist, in hereditary angioedema [Clinical Trial, Phase III, Multicenter Study, Randomized Controlled Trial, Research Support, N.I.H., Extramural, Research Support, Non-US Gov't]. N Engl J Med 2010; 363:532-541. doi: 10.1056/NEJMoa0906393.
40. Greve J, Hoffmann TK, Schuler P, et al. Successful long-term treatment with the bradykinin B2 receptor antagonist icatibant in a patient with hereditary angioedema [Research Support, Non-US Gov't]. Int J Dermatol 2011; 50:1294-1295. doi: 10.1111/j.1365-4632.2011.05051.x.
41. http://pi.shirecontent.com/PI/PDFs/Firazyr-USA-ENG.pdf. [Accessed 21 November 2011]
42. Varga L, Farkas H. rhC1INH: a new drug for the treatment of attacks in hereditary angioedema caused by C1-inhibitor deficiency. Expert Rev Clin Immunol 2011; 7:143-153. doi: 10.1586/eci.11.5.
43. Zuraw B, Cicardi M, Levy RJ, et al. Recombinant human C1-inhibitor for the treatment of acute angioedema attacks in patients with hereditary angioede-ma [Randomized Controlled Trial, Research Support, Non-US Gov't, Research Support, US Gov't, Non-PHS]. J Allergy Clin Immunol 2010; 126:821-827; e814. doi: 10.1016/j.jaci.2010.07.021.
44. Davis B, Bernstein JA. Conestat alfa for the treatment of angioedema attacks. Ther Clin Risk Manag 2011; 7:265-273. doi: 10.2147/TCRM.S15544.
45. Caballero T, Baeza ML, Cabanas R, et al. Consensus statement on the diagnosis, management, and treatment of angioedema mediated by brady-kinin. Part II. Treatment, follow-up, and special situations [Consensus Devel opment Conference, Review]. J Investig Allergol Clin Immunol 2011; 21:422-441; quiz 442-443.
46. Frank MM. Update on preventive therapy (prophylaxis) of hereditary angioe-dema [Research Support, Non-US Gov't]. Allergy Asthma Proc 2011; 32:17-21. doi: 10.2500/aap.2011.32.3412.
47. Maurer M, Magerl M. Long-term prophylaxis of hereditary angioedema with androgen derivates: a critical appraisal and potential alternatives [Compara tive Study, Review]. J Dtsch Dermatol Ges 2011; 9:99-107. doi: 10.1111/j.1610-0387.2010.07546.x.
48. Zanichelli A, Vacchini R, Badini M, et al. Standard care impact on angioedema because of hereditary C1 inhibitor deficiency: a 21-month prospective study in a cohort of 103 patients [Research Support, Non-US Gov't]. Allergy 2011; 66:192-196. doi: 10.1111/j.1398-9995.2010.02433.x.
49. Tallroth GA. Long-term prophylaxis of hereditary angioedema with a pasteur ized C1 inhibitor concentrate [Case Reports]. Int Arch Allergy Immunol 2011; 154:356-359. doi: 10.1159/000321830.
50. Cicardi M, Bork K, Caballero T, et al. Evidence-based recommendations for the therapeutic management of angioedema owing to hereditary C1 inhibitor deficiency: consensus report of an International Working Group [Research Support, Non-US Gov't]. Allergy 2012; 67:147-157. doi: 10.1111/j.1398-9995.2011. 02751.x.
51. Riedl M, Gower RG, Chrvala CA. Current medical management of hereditary angioedema: results from a large survey of US physicians [Research Support, Non-US Gov't]. Ann Allergy Asthma Immunol 2011; 106:316-322. doi: 10.1016/j.anai.2010.12.012.
52. Kreuz W, Rusicke E, Martinez-Saguer I, et al. Home therapy with intravenous human C1-inhibitor in children and adolescents with hereditary angioedema. Transfusion 2012; 52:100-107. doi: 10.1111/j.1537-2995.2011.03240.x.